Tipifarnib in Subjects With Myelodysplastic Syndromes

NCT02779777 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Tipifarnib

Sponsor

Kura Oncology, Inc.